[{"symbol": "IBRX", "publishedDate": "2026-01-19 11:40:12", "title": "ImmunityBio Shares Surge on Updated Durable Lymphoma Study Results", "image": "https://images.financialmodelingprep.com/news/immunitybio-shares-surge-on-updated-durable-lymphoma-study-results-20260119.jpg", "site": "zacks.com", "text": "IBRX shares surge after updated data from the study of CD19 t-haNK show durable complete responses in Waldenstrom lymphoma without chemo or lymphodepletion.", "url": "https://www.zacks.com/stock/news/2819476/immunitybio-shares-surge-on-updated-durable-lymphoma-study-results?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2819476"}, {"symbol": "IBRX", "publishedDate": "2026-01-16 16:57:23", "title": "Stock Market Today, Jan. 16: ImmunityBio Soars After Anktiva Revenue Jumps 700 Percent Year Over Year", "image": "https://images.financialmodelingprep.com/news/stock-market-today-jan-16-immunitybio-soars-after-anktiva-20260116.jpg", "site": "fool.com", "text": "Explosive Anktiva sales, new cancer data, and fresh approvals are rapidly redefining this immunotherapy story, today, Jan. 16, 2026.", "url": "https://www.fool.com/coverage/stock-market-today/2026/01/16/stock-market-today-jan-16-immunitybio-soars-after-anktiva-revenue-jumps-700-percent-year-over-year/"}, {"symbol": "IBRX", "publishedDate": "2026-01-16 15:45:59", "title": "ImmunityBio, Inc. (IBRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript", "image": "https://images.financialmodelingprep.com/news/immunitybio-inc-ibrx-presents-at-44th-annual-jp-morgan-20260116.jpg", "site": "seekingalpha.com", "text": "ImmunityBio, Inc. (IBRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript", "url": "https://seekingalpha.com/article/4860600-immunitybio-inc-ibrx-presents-at-44th-annual-j-p-morgan-healthcare-conference-transcript"}, {"symbol": "IBRX", "publishedDate": "2026-01-16 13:45:22", "title": "Why ImmunityBio Stock Is Skyrocketing Again Today", "image": "https://images.financialmodelingprep.com/news/why-immunitybio-stock-is-skyrocketing-again-today-20260116.jpg", "site": "fool.com", "text": "ImmunityBio announced this morning that it had reached a major enrollment threshold for one of its clinical trials. It also highlighted initial success in treating patients with Non-Hodgkin lymphoma with one of its next-gen therapies.", "url": "https://www.fool.com/investing/2026/01/16/why-immunitybio-stock-is-skyrocketing-again-today/"}, {"symbol": "IBRX", "publishedDate": "2026-01-16 12:52:36", "title": "ImmunityBio Stock Soars On Cancer Trial Progress, FDA Timeline", "image": "https://images.financialmodelingprep.com/news/immunitybio-stock-soars-on-cancer-trial-progress-fda-timeline-20260116.jpg", "site": "benzinga.com", "text": "ImmunityBio Inc. (NASDAQ: IBRX) stock has surged more than 100% year to date after the upbeat fourth-quarter preliminary results and trial data.", "url": "https://www.benzinga.com/news/health-care/26/01/49973099/immunitybio-stock-soars-on-cancer-trial-progress-fda-timeline"}]